GERD (gastroesophageal reflux disease) has seen a significant advancement with Phathom Pharmaceuticals announcing the FDA approval of Voquezna for the treatment of non-erosive GERD. This condition, which causes heartburn, now has a new treatment option with Voquezna. This marks the third FDA approval for Voquezna, which is also approved for treating all severities of erosive esophagitis and for eradicating H. pylori infection when used with antibiotics.
In a press release, Phathom CEO and president Terrie Curran highlighted the importance of this approval: “Today marks a significant milestone for millions of GERD patients as we proudly announce the approval of Voquezna for the treatment of Non-Erosive GERD. For decades GERD sufferers had no new class of treatment to turn to in the U.S. This approval provides patients and healthcare providers with immediate access to the first and only FDA-approved treatment of its kind, from a new class of acid suppression therapy, and the power to help provide complete 24-hour heartburn-free days and nights. We are very excited to introduce Voquezna to the broader GERD community and look forward to its potential to help change the way this disease is treated.”
GERD Breakthrough: Voquezna Approval Offers New Hope for Non-Erosive GERD Patients
Colin W. Howden, MD, professor emeritus at the University of Tennessee’s College of Medicine, also commented on the approval: “Millions of patients with Non-Erosive GERD continue to suffer from heartburn despite current treatment options. The pivotal study that led to this approval showed that Voquezna significantly reduced heartburn episodes in patients with Non-Erosive GERD along with an established safety profile. Today’s approval of Voquezna provides physicians with a novel, first-in-class treatment that can quickly and significantly reduce heartburn for many adult patients.”
The approval followed a Phase III study presented by Phathom at the Digestive Disease Week conference in Washington D.C., investigating Voquezna as a treatment for non-erosive reflux disease (NERD). In a press release at the time, Phathom’s chief medical officer Eckhard Liefke, MD, stated: “This year’s abstracts showcase the breadth of the data we will be presenting at DDW, reaffirming Phathom’s continued commitment to helping improve the lives of people affected by acid-related gastrointestinal disorders. Notably, we are excited to unveil novel findings highlighted in three posters and an oral presentation during the conference, including the first-time data from our Phase 3 study of the investigational use of Voquezna in Non-Erosive GERD will be presented during a medical congress. Our team eagerly anticipates meaningful interactions with physicians that treat the conditions we are working to transform.”
Earlier this year, Phathom launched a direct-to-consumer advertising campaign for Voquezna, featuring on various platforms such as Facebook, Instagram, and in waiting rooms of doctors’ offices. The campaign, tagged “Voquezna can kick some acid,” aims to raise awareness and connect with patients unsatisfied with current treatment options.
GERD Awareness: Phathom Launches Voquezna Campaign to Address Unmet Needs
Martin Gilligan, Phathom’s chief commercial officer, emphasized the campaign’s goal: “Phathom is excited to launch our first campaign directly to, and for, the people whose lives we strive to improve every day. Although Erosive GERD is a highly symptomatic condition that can have a detrimental impact on millions of patients, there has been little medical innovation in this category in decades, until now. We believe our new DTC campaign is accessible, memorable, and informative. Our goal is to connect with people unsatisfied with their current treatment options and empower them to explore the power of Voquezna with their healthcare provider.”
Voquezna’s approval represents a significant advancement for GERD patients, providing a new class of treatment that offers complete 24-hour relief from heartburn. This innovative acid suppression therapy is expected to change the management of GERD, offering hope to millions who suffer from this chronic condition. Phathom Pharmaceuticals continues to demonstrate its commitment to improving gastrointestinal health and addressing unmet medical needs through innovative therapies.
In conclusion, the FDA approval of Voquezna for non-erosive GERD is a breakthrough in the treatment of this common yet challenging condition. With its unique mechanism of action and proven efficacy, Voquezna is set to become a vital tool in the arsenal against GERD, helping patients achieve better control over their symptoms and improve their quality of life.
GERD (gastroesophageal reflux disease) has seen a significant advancement with Phathom Pharmaceuticals announcing the FDA approval of Voquezna for the treatment of non-erosive GERD. This condition, which causes heartburn, now has a new treatment option with Voquezna. This marks the third FDA approval for Voquezna, which is also approved for treating all severities of erosive esophagitis and for eradicating H. pylori infection when used with antibiotics.
Resource: <a href="https://investors.phathompharma.com/news-releases/news-release-details/phathom-pharmaceuticals-announces-fda-approval-voqueznar-0″>Phatom Pharma, July 18, 2024
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
